Breathing Easy: Prioritizing Children’s Health on Clean Air Day
Key Takeaways
Children are disproportionately affected by air pollution, with lifelong health consequences stemming from exposure during critical developmental stages.
Policy advocacy, clean transport, and urban planning are key levers for improving air quality and protecting children’s health.
Healthcare professionals play a crucial role in raising awareness and influencing environmental and public health decisions.
The European Academy of Paediatrics (EAP) and partners are committed to advancing research, education, and advocacy for clean air policies across Europe.
Collaboration between medical societies, local authorities, and civil society is essential for impactful change.
📊 Learn the evidence. 💡 Discover practical strategies.
🎯 Be part of the movement to make every breath safer.
🌍 Paediatricians are powerful advocates.
Let’s raise our voices together.
Spotlight on a Key Question
Yes, although this is still an emerging field of research, several studies suggest a possible link between early-life air pollution exposure and later neurodevelopmental and neurodegenerative outcomes.
While this is not the Dutch Lung Foundation’s core expertise, the following publications offer valuable insights:
Air pollution, a rising environmental risk factor for cognition, neuroinflammation and neurodegeneration (2021):
https://pubmed.ncbi.nlm.nih.gov/26718591/
Prenatal exposure to air pollution and neurodevelopmental outcomes at ages 1 to 3 years (2024):
https://pubmed.ncbi.nlm.nih.gov/39478594/
Ambient particulate matter and its potential neurological consequences (2025):
https://doi.org/10.1515/revneuro-2013-0001
Particulate matter exposure and neurodegenerative diseases: A comprehensive update (2023):
https://pubmed.ncbi.nlm.nih.gov/37832485/
About the Presenters
Presenter
Primary Care Paediatrician (retired) & Co-chair EAP SAG on Climate Change and Planetary health, Member of IPA Environmental Health & Climate Change | President of the European Confederation of Primary Care Paediatricians (ECPCP)
Presenter
Director, Lung Foundation Netherlands (Longfonds), Former Chairman, Dutch Paediatric Association Member, Dutch Outbreak Management Team (OMT), Vice Chairman, Supervisory Board, Pantein Zorggroep
Presenter
Sherwood Forest Hospitals NHS Foundation Trust - Associate Medical Director & Climate Action Clinical Lead, Royal College of Paediatrics and Child Health (RCPCH) - Officer for Climate Change, Nottinghamshire Greener ICS Board - Chair, Clinical Advisory Group, Midlands Clinical Senate - Collaborator on Climate and Health
Presenter
Research Manager, Royal College of Paediatrics and Child Health (RCPCH), United Kingdom
Moderator - Young EAP Rep. | Italy
Lorenza Onorati is a pediatrician (medico in formazione) at the University of Padova’s Department of Women’s and Children’s Health.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.